Results 221 to 230 of about 693,900 (279)

Impact of adverse events-associated dose modifications of PARP inhibitors on treatment outcomes in primary ovarian cancer. [PDF]

J Ovarian Res
Fu Y, Xu Z, Li X, Mu Y, Guo X, Zhang W, Liu S.   +6 more
europepmc   +1 more source

Clinical Implementation and Oncological Relevance of Molecular Profiling in Brain Metastases Patients—A Multicenter Retrospective Cohort Study

International Journal of Cancer, Volume 159, Issue 10, Page 2562-2574, 15 November 2026.
While current guidelines recommend the analysis of established cancer driver genes in brain metastases, little is known about its real‐life implementation. This multicenter study revealed an upward trend in the profiling rates of surgically treated brain metastases over the past decade, with up to 60% of brain metastases samples undergoing analysis ...
Maria Nikolaeva, Jacopo Bellomo, Meltem Gönel, Vittorio Stumpo, Victor Egon Staartjes, Flavio Vasella, Kevin Akeret, André Sagerer, Anna Maria Zeitlberger, David Wasilewski, Christopher Krämer, Sven König, Julia Onken, Tareq Juratli, Alexander Köpp, Regina Reimann, Marcus Czabanka, Peter Vajkoczy, Ilker Y. Eyüpoglu, Oliver Bozinov, Michael Weller, Emilie Le Rhun, Luca Regli, Carlo Serra, Marian C. Neidert, Stefanos Voglis   +25 more
wiley   +1 more source

Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis. [PDF]

Front Immunol
Zhang H, Yan G, Yan J, Zeng X.
europepmc   +1 more source

Infant Embryonal CNS Tumors: Molecular Insights and Treatment Considerations for Contemporary Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, Volume 73, Issue 11, November 2026.
ABSTRACT Background Embryonal tumors comprise the majority of malignant central nervous system (CNS) neoplasms diagnosed in children under 3 years of age. Compared with their counterparts in older children, these tumors exhibit distinct molecular biology and a more aggressive clinical phenotype, while their management is complicated by the heightened ...
Sudarshawn Damodharan, Mariah Wright‐Nadkarni, Mohamed S. Abdelbaki, Girish Dhall   +3 more
wiley   +1 more source

Denosumab Combined With PARP Inhibitors and Chemoradiotherapy for Treating Triple Negative Breast Cancer With Bone Metastasis: A Case Report. [PDF]

Cancer Rep (Hoboken)
Liu L, Yu L, Wang Y, Zhang H, Zhang X.
europepmc   +1 more source

Metformin Sensitizes PTEN-deficient Prostate Cancer to PARP Inhibitors by Rebuilding NADP⁺ Homeostasis. [PDF]

Int J Biol Sci
Hao X, Chao Z, Peng H, Guo X, Zheng S, Zhang C, Ding H, Wang Y, Xi Z, Gao Y, Qu G, Zhu Y, Chen Z, Lan P, Li L, Wang Z.   +15 more
europepmc   +1 more source

Toxicities of PARP inhibitors in genitourinary cancers. [PDF]

Curr Opin Urol
Szalontai J, Szarvas T, Miszczyk M, Nyirády P, Shariat SF, Fazekas T.   +5 more
europepmc   +1 more source

Patient-derived organoids predict responses to chemotherapy and PARP inhibitors in advanced ovarian cancer. [PDF]

J Transl Med
Wang H, Wang L, Zhu X, He M, Zhong L, Lv Y, Li Q, Jiang Q, Zhang C, Liu X, Zou D.   +10 more
europepmc   +1 more source

Global research trends in PARP inhibitors for ovarian cancer: a bibliometric analysis. [PDF]

Discov Oncol
Wang X, Ding G, He J, Huang Y, Wang Q.
europepmc   +1 more source

PARP inhibitors for cancer therapy

Expert Reviews in Molecular Medicine, 2005
Poly(ADP-ribose) polymerase 1 (PARP-1) is a zinc-finger DNA-binding enzyme that is activated by binding to DNA breaks. Poly(ADP-ribosyl)ation of nuclear proteins by PARP-1 converts DNA damage into intracellular signals that activate either DNA repair by the base-excision pathway or cell death. A family of 18 PARPs has been identified, but only the most
Curtin NJ
core   +9 more sources